Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBIT (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed EBIT for 7 consecutive years, with -$42.4 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 29.9% to -$42.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$209.3 million through Dec 2025, up 23.38% year-over-year, with the annual reading at -$209.3 million for FY2025, 23.38% up from the prior year.
  • EBIT hit -$42.4 million in Q4 2025 for Allogene Therapeutics, up from -$44.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $1.7 million in Q4 2021 to a low of -$99.1 million in Q1 2023.
  • Historically, EBIT has averaged -$66.3 million across 5 years, with a median of -$71.2 million in 2021.
  • Biggest five-year swings in EBIT: soared 102.46% in 2021 and later crashed 5747.04% in 2022.
  • Year by year, EBIT stood at $1.7 million in 2021, then plummeted by 5747.04% to -$96.4 million in 2022, then rose by 11.71% to -$85.1 million in 2023, then increased by 28.93% to -$60.5 million in 2024, then increased by 29.9% to -$42.4 million in 2025.
  • Business Quant data shows EBIT for ALLO at -$42.4 million in Q4 2025, -$44.9 million in Q3 2025, and -$56.8 million in Q2 2025.